306 results on '"Higazi, Abd Al-Roof"'
Search Results
2. Characterization of metabolic alterations in the lean metabolically unhealthy alpha defensin transgenic mice
Catalog
Books, media, physical & digital resources
3. Neutrophil α-defensins promote thrombosis in vivo by altering fibrin formation, structure, and stability
4. RETRACTED ARTICLE: Release of IL-6 After Stroke Contributes to Impaired Cerebral Autoregulation and Hippocampal Neuronal Necrosis Through NMDA Receptor Activation and Upregulation of ET-1 and JNK
5. Alleviation of Hepatic Steatosis by Alpha-Defensin Is Associated with Enhanced Lipolysis
6. α-Defensins Induce a Post-translational Modification of Low Density Lipoprotein (LDL) That Promotes Atherosclerosis at Normal Levels of Plasma Cholesterol
7. Tissue plasminogen activator involvement in experimental autoimmune myasthenia gravis: Aggravation and therapeutic potential
8. Urokinase-type Plasminogen Activator (uPA) Induces Pulmonary Microvascular Endothelial Permeability through Low Density Lipoprotein Receptor-related Protein (LRP)-dependent Activation of Endothelial Nitric-oxide Synthase
9. tPA contributes to impairment of ATP and Ca sensitive K channel mediated cerebrovasodilation after hypoxia/ischemia through upregulation of ERK MAPK
10. Tissue-Type Plasminogen Activator-A296–299 Prevents Impairment of Cerebral Autoregulation After Stroke Through Lipoprotein-Related Receptor–Dependent Increase in cAMP and p38
11. PAI-1-Derived Peptide EEIIMD Prevents Hypoxia/Ischemia-Induced Aggravation of Endothelin- and Thromboxane-Induced Cerebrovasoconstriction
12. Divergent impacts of tocilizumab and colchicine in COVID‐19‐associated coagulopathy: the role of alpha‐defensins
13. Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile
14. RBC-coupled tPA Prevents Whereas tPA Aggravates JNK MAPK-Mediated Impairment of ATP- and Ca-Sensitive K Channel-Mediated Cerebrovasodilation After Cerebral Photothrombosis
15. Nuclear translocation of urokinase-type plasminogen activator
16. uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK
17. Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK
18. PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia
19. Inhibition of integrin [[alpha].sub.v][[beta].sub.3] prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia
20. Alpha‐defensins: risk factor for thrombosis in COVID‐19 infection
21. α-Defensin: Link between inflammation and atherosclerosis
22. LRP and [[alpha].sub.v][[beta].sub.3] mediate tPA activation of smooth muscle cells
23. The structure of lipoprotein(a) and ligand-induced conformational changes
24. Urokinase Plasminogen Activator Regulates Pulmonary Arterial Contractility and Vascular Permeability in Mice
25. ACE2, COVID-19 Infection, Inflammation, and Coagulopathy: Missing Pieces in the Puzzle
26. Opposing effects of HNP1 (α-defensin-1) on plasma cholesterol and atherogenesis
27. Regulation of Airway Contractility by Plasminogen Activators through N-Methyl-D-Aspartate Receptor-1
28. Neutrophil α-Defensins Cause Lung Injury by Disrupting the Capillary-Epithelial Barrier
29. uPA Modulates the Age-Dependent Effect of Brain Injury on Cerebral Hemodynamics through LRP and ERK MAPK
30. Regulation of the single-chain urokinase–urokinase receptor complex activity by plasminogen and fibrin: novel mechanism of fibrin specificity
31. Divergent impacts of tocilizumab and colchicine in COVID‐19‐associated coagulopathy: the role of alpha‐defensins.
32. Inhibition of neutrophil activation by fibrinogen
33. α-Defensins
34. Plasminogen Activators Contribute to Impairment of Hypercapnic and Hypotensive Cerebrovasodilation After Cerebral Hypoxia/Ischemia in the Newborn Pig
35. Unesterified long chain fatty acids inhibit the binding of single chain urokinase to the urokinase receptor
36. In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone
37. Interactions of Platelet Factor 4 with the Vessel Wall
38. The kringle stabilizes urokinase binding to the urokinase receptor
39. Platelet Factor 4 Enhances the Binding of Oxidized Low-density Lipoprotein to Vascular Wall Cells
40. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo
41. Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo
42. Human α-defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor–related protein/α2-macroglobulin receptor
43. Binding of Urokinase to Low Density Lipoprotein-related Receptor (LRP) Regulates Vascular Smooth Muscle Cell Contraction
44. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface
45. A Region in Domain II of the Urokinase Receptor Required for Urokinase Binding
46. Urokinase mediates fibrinolysis in the pulmonary microvasculature
47. The α-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflammatory apolipoprotein and a possible contributor to atherogenesis
48. Novel Interactions between Urokinase and Its Receptor
49. Release of IL-6 After Stroke Contributes to Impaired Cerebral Autoregulation and Hippocampal Neuronal Necrosis Through NMDA Receptor Activation and Upregulation of ET-1 and JNK
50. Abstract TP251: Release of IL-6 After Stroke Contributes to Impaired Cerebral Autoregulation and Hippocampal Neuronal Necrosis Through NMDA Receptor Activation and Upregulation of ET-1 and JNK
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.